Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-...
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Monoclonal antibodies (MAbs), convalescent plasma (CP) and hyperimmune intravenous immunoglobulins are routinely used to treat COVID-19 patients with autoimmune disorders, organ transplant patients and patients on immunosuppressive drugs. The recent emergence of rapidly spreading SARS-CoV-2 variant of concern (VOC), omicron, contains large number o...
Alternative Titles
Full title
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2628295655
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2628295655
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2022-222115
